KNTPF (Kintor Pharmaceutical) Total Assets: $48.39 Mil (As of Dec. 2025)


KNTPF Kintor Pharmaceutical Ltd KNTPF
24 GF Score
Price $0.34
! 3 Warning Signs
View Full Analysis

What is Kintor Pharmaceutical Total Assets?

Kintor Pharmaceutical KNTPF 24 Total Assets is $48.39 Mil as of Dec. 2025. GuruFocus rates KNTPF with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Kintor Pharmaceutical's Total Assets for the quarter that ended in Dec. 2025 was $48.39 Mil.

During the past 12 months, Kintor Pharmaceutical's average Total Assets Growth Rate was -13.30% per year. During the past 3 years, the average Total Assets Growth Rate was -36.30% per year. During the past 5 years, the average Total Assets Growth Rate was -17.90% per year.

During the past 8 years, Kintor Pharmaceutical's highest 3-Year average Total Assets Growth Rate was 56.30%. The lowest was -36.30%. And the median was -6.20%.

Total Assets is connected with ROA %. Kintor Pharmaceutical's annualized ROA % for the quarter that ended in Dec. 2025 was -64.44%. Total Assets is also linked to Revenue through Asset Turnover. Kintor Pharmaceutical's Asset Turnover for the quarter that ended in Dec. 2025 was 0.07.

Kintor Pharmaceutical  (OTCPK:KNTPF) Total Assets Explanation

Total Assets is connected with ROA %.

Kintor Pharmaceutical's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-33.178/( (54.578+48.388)/ 2 )
=-33.178/51.483
=-64.44 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Kintor Pharmaceutical's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=3.791/( (54.578+48.388)/ 2 )
=3.791/51.483
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Kintor Pharmaceutical Total Assets Related Terms

Kintor Pharmaceutical Total Assets Historical Data

* Premium members only.

The historical data trend for Kintor Pharmaceutical's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kintor Pharmaceutical Total Assets Chart

Kintor Pharmaceutical Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial 324.68 294.78 121.74 70.75 48.39

Kintor Pharmaceutical Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 121.74 101.94 70.75 54.58 48.39
KNTPF
24GF Score
Kintor Pharmaceutical Ltd KNTPF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kintor Pharmaceutical Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Kintor Pharmaceutical's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=25.925+22.463
=48.39

Kintor Pharmaceutical's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=25.925+22.463
=48.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $48.39 Mil mean?
Kintor Pharmaceutical (KNTPF) has a Total Assets of $48.39 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Kintor Pharmaceutical and its competitors.
Is Kintor Pharmaceutical's Total Assets too high?
Kintor Pharmaceutical's current Total Assets is $48.39 Mil. Overall, Kintor Pharmaceutical has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Kintor Pharmaceutical's Total Assets compare to VRTX and REGN?
Kintor Pharmaceutical's Total Assets of $48.39 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Kintor Pharmaceutical and its competitors. Kintor Pharmaceutical's current Total Assets is $48.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kintor Pharmaceutical stock overvalued right now?
Kintor Pharmaceutical (KNTPF) has a current Total Assets of $48.39 Mil. The current Total Assets is $48.39 Mil. Kintor Pharmaceutical's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Kintor Pharmaceutical (KNTPF), the current Total Assets is $48.39 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kintor Pharmaceutical Business Description

Other Exchanges 09939:Hong Kong
Address No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China, focusing on developing therapeutic drugs for unmet medical needs. Its pipelines cover indications of dermatology, such as AGA and acne vulgaris, and indications of tumors, catering to the unmet medical needs of patients and cosmetics consumers globally. The Group's cosmetic product types include anti-hair loss, acne treatment, and skin whitening products. Kintor's pipeline consists of various drug candidates such as KX-826, AR-PROTAC Compound (GT20029), GT1708F (Hedgehog/SMO Inhibitor), GT0486, and ALK-1 Antibody (GT90001). It has only one reportable operating segment, which is engaged in the research and development of medicine products and extends to functional cosmetics and raw materials.
24GF Score

Get the complete analysis for KNTPF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.34
Price